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Abstract 
Purpose. To evaluate by simulation the statistical properties of normalized prediction 
distribution errors (NPDE), prediction discrepancies (pd), standardized prediction errors 
(SPE), numerical predictive check (NPC) and decorrelated NPC (NPCdec) for the external 
evaluation of a population pharmacokinetic analysis, and to illustrate the use of NPDE for the 
evaluation of covariate models. 
Methods.  
We assume that a model MB has been built using a building dataset B, and that a separate 
validation dataset, V is available. Our null hypothesis H0 is that the data in V can be described 
by MB. We use several methods to test this hypothesis: NPDE, pd, SPE, NPC and NPCdec. 
First, we evaluated by simulation the type I error under H0 of different tests applied to the four 
methods. We also propose and evaluate a single global test combining normality, mean and 
variance tests applied to NPDE, pd and SPE. We perform tests on NPC and NPCdec, after a 
decorrelation. MB was a one compartment model with first order absorption (without 
covariate), previously developed from two phase II and one phase III studies of the 
antidiabetic drug, gliclazide. We simulated 500 external datasets  according to the design of a 
phase III study. 
Second, we investigated the application of NPDE to covariate models. We propose two 
approaches: the first approach uses correlation tests or mean comparisons to test the 
relationship between NPDE and covariates; the second evaluates NPDE split by category for 
discrete covariates or quantiles for continuous covariates. We generated several validation 
datasets under H0 and under alternative assumptions with a model without covariate, with one 
continuous covariate (weight), or one categorical covariate (sex). We calculated the powers of 
the different tests using simulations, where the covariates of the phase III study were used.  
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Results. The simulations under H0 show a high type I error for the different tests 
applied to SPE and an increased type I error for pd. The different tests present a type I error 
close to 5% for for the global test appied to NPDE. We find a type I error higher than 5% for 
the test applied to classical NPC but this test becomes close to 5% for NPCdec. 
For covariate models, when model and validation dataset are consistent, type I error of the 
tests are close to 5% for both effects. When validation datasets and models are not consistent, 
the tests detect the correlation between NPDE and the covariate.  
 
Conclusion. We recommend to use NPDE over SPE for external model evaluation, since they 
do not depend on an approximation of the model and have good statistical properties. NPDE 
represent a better approach than NPC, since in order to perform tests on NPC, a decorrelation 
step must be applied before. NPDE, in this illustration, is also a good tool to evaluate model 
with or without covariates.  
 
KEY WORDS: model evaluation, population pharmacokinetics, predictive distribution, VPC, 
NPC, predictive check, prediction error
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INTRODUCTION 
The Food and Drugs Administration (FDA) performed a survey to evaluate the impact of 
population pharmacokinetic (PK) and/or pharmacodynamic (PD) analyses on drug approval 
and labelling decisions between 2000 and 2004 and an article concerning evolution and 
impact of pharmacometrics at FDA (1). They pointed out in their survey that, in order for the 
information resulting from a population analysis to be useful during regulatory assessment, 
the analysis needs to be of sufficient quality so that the final model can be judged to be a good 
description of the data and that the results ensuing from the population analysis can be 
considered valid. The guideline of the European Agency of Evaluation of Medicinal Products 
(EMEA) on reporting the results of population pharmacokinetic analyses, in 2006, 
recommends to use model evaluation procedures to demonstrate that the final model is robust 
and is a sufficiently good description of the data so that the objective(s) of the analysis can be 
met (2). The FDA guidelines on population analyses also fully supports the use of population 
PK and/or PD modeling during drug development process, and stresses the need for model 
evaluation. Two types of model evaluation can be performed (3). The first is internal 
evaluation, which compares an original dataset used for the model building (called learning 
dataset); in the following here, we only consider the second one, more stringent, external 
evaluation, which refers to a comparison between a separate dataset (usually called validation 
dataset) and the predictions from the model built from the learning dataset using dosage 
regimen information and possibly covariates from the validation dataset. The validation 
dataset is not for model building or for parameter estimation. However evaluations methods 
described here could be applied for internal model evaluation too. 
Mentré and Escolano developed a new model evaluation method, called prediction 
discrepancies (pd), and showed that pd exhibit have better statistical properties than 
standardized prediction errors SPE (usually called weighted residual or WRES), the most 
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frequently used metric according to a survey investigating PK/PD analyses in 2005 and 2006 
(4), but that multiple observations per subject increased the type I error of the test (5). 
In a recent paper, we defined and illustrated metrics for external evaluation of a 
population model(6). In particular, we proposed an improved version of pd. This improved 
version presents better theoretical statistical properties with multiple observations per subject 
by taking into account correlations and was called Normalized prediction errors (NPDE) (6).  
In the present paper, we now evaluate in a simulation study the properties of different 
tests applied to NPDE; we compare these results to those obtained both with the historical 
method, SPE, and with the pd from which the NPDE were derived, to see the benefit of taking 
into account correlations within an individual. We also compare NPDE with a related statistic 
based on the visual predictive check (VPC). VPC are a graphical comparison between the 
observations and the simulated predictive distribution. The simulated data used for the VPC 
can be used to derive a related statistic, called numerical predictive check (NPC) (8). We  
apply two tests, a Student test and a binomial exact test, to test whether the percentage of 
observations in a given prediction interval match the theoretical coverage. We evaluate and 
compare using simulations the properties of these two tests on the classical NPC, and on an 
extension to this NPC developed here: the decorrelated numerical predictive check (NPCdec). 
The model used to perform simulations under H0 in order to evaluate the type I error of 
different tests applied to SPE, NPDE, pd, NPC and NPCdec was a population pharmacokinetic 
model of gliclazide, built from concentrations measured in two phase II studies and one phase 
III study (9). The validation datasets are simulated using the design of a real phase III study.  
We then extend the application of NPDE to evaluate different models with a covariate 
by generating several validation datasets under alternative assumptions: without covariate, 
with one continuous covariate, with one categorical covariate.  
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POPULATION PHARMACOKINETIC MODEL OF GLICLAZIDE  
Data 
We used four clinical studies, which were performed during the clinical development of a 
modified release formulation of gliclazide (gliclazide MR), an oral antidiabetic agent. They 
were part of a larger dataset analyzed by Frey et al.(9), who studied the relationship between 
the pharmacokinetics of gliclazide and its long-term PD effect. The first phase II study (N = 
40 patients, 18 observations per subject) was a ascending-dose study of gliclazide MR. The 
second one (N = 169 patients, 6 observations per subject) was a dose ranging, monocentric 
study of gliclazide MR. The two phase III studies (N = 462 patients and 351, respectively, 3 
observations per subject for each study) were clinical comparative trials of gliclazide MR with 
the currently formulation of gliclazide in different countries, with a titration period of 4 
months, a maintenance period of 6 months and a follow up period of 2 months. At the end of 
these phases III studies, all patients received gliclazide MR. The designs of these four studies 
have been described in details by Frey et al(9). . Gliclazide plasma concentrations were 
measured using high-performance liquid chromatography with ultaviolet detection. 
 
Basic model building 
We developped the population pharmacokinetic model for gliclazide MR, from the two phase 
II studies and the first phase III study, in a total of 642 Type II diabetic patients with 5931 
plasma concentrations of gliclazide. The last phase III study was used as an external 
validation dataset for model evaluation. 
During model building, we tested a zero order or a first order absorption model with or 
without a lag time. We assumed an exponential random-effect model to describe inter-
individual variability. For residual variability, three error models were tested: additive, 
proportional and combined error model. The existence of a correlation between the PK 
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parameters was also tested. Model selection was based on comparison of the objective 
function. The decision to include a parameter in the model was based on the Likelihood ratio 
test (LRT). The objective function obtained in NONMEM is up to a constant equal to –2log 
likelihood. The difference in objective function (likelihood ratio) between two nested models 
(i.e. the larger model can be reduced to the smaller) is approximately chi square distributed, 
with degrees of freedom (df) equal to the difference in the number of parameters. Based on 
this, the improvement here in model fit from the inclusion (or deletion) of a model parameter 
can be assigned a significance level; 3.84 corresponds to nominal p value of <0.05 (df=1). 
Non-nested models were compared using the Akaike criterion (AIC).  
During model building, values below the quantification limit (BQL), with a 
quantification limit (QL) which was equal to 0.05 mg/l, were treated in one of the standard 
ways by imputing the first BQL measurement to QL/2 and omitting subsequent BQL 
measurements during the terminal phase (10). The symmetrical reverse procedure was applied 
to BQL measurements during the absorption phase.  
 
 
Covariate model building 
From the final basic model, the effects of covariates on the Empirical Bayes Estimates (EBE) 
of each individual random effects, were tested using non parametric tests: a Wilcoxon Mann-
Whitney test for categorical variables and a Spearman correlation test for continuous 
variables. Non parametric statistical tests were carried out to identify potential covariates of 
interest to save time during covariate model building. The tested covariates were: age, sex, 
race, weight, body mass index, creatinine, creatinine clearance (calculated from the Cockcroft 
and Gault formula), total plasma protein, alcohol habit, hepatic disease, drug interaction and 
dose. For drug interaction, as the principal routes of gliclazide metabolism are catalysed by 
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CYP2C9 and CYP2C19 enzyme, categorical covariates were defined for each co-
administratered substrate, inhibitor or inducer of these enzymes. These covariates took the 
value of 1 in case of co-administration, and 0 otherwise. 
The covariate model was then built with the covariates which were found to have a 
significant effect in this first step (p<0.05). The population models corresponding to all the 
combinations of these candidate covariates were evaluated. Let i be an individual PK 
parameter of the i
th
 subject,  the population PK parameter and COV a covariate effect on . 
For a continuous covariate, COVi was the covariate value in the i
th
 patient and MEANCOV the 
arithmetic mean. For categorical covariates, COVi was an indicator variable of the i
th
 patient, 
with a value of 1 when the characteristic was present in the i
th
 patient, 0 otherwise. i 
represents the vector of random effect of individual i. For a continuous covariate, the 
covariate model was implemented with the equation: 
i = [ + COV × (COVi – MEANCOV)] × exp(i)  (1) 
The equation for the covariate model of a categorical covariate was: 
i = [ × (1 + COV × COVi)] × exp(i)   (2) 
The decision to include a covariate in the model was also based on the LRT. From the 
best model with the smallest AIC, a backward elimination procedure was then used to test 
whether all covariates selected should remain in the final model using a LRT with a value of p 
= 0.005. 
The population analysis of the two phase II studies and the one phase III study was 
performed using NONMEM software version V (University of San Francisco) with the FO 
method.  
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Results 
Data, which are normalized for a dose of 30 mg, are dispayed in figure 1; the 90% 
predicted interval, obtained as the 5
th
 and 95
th
 percentiles of 1000 simulations are surimposed 
on the observations on the top plot and the 10
th
, 50
th
 and 90
th
 percentiles of 1000 simulations 
are superimposed on the 10
th
, 50
th
 and 90
th
 percentiles of the observations on the bottom plot. 
We decided here in the second plot to represent the percentiles of the observations and not the 
observations themselves; there is less need for displaying the observations as the percentiles 
will reveal where the information in data is rich and where it is sparse. This VPC was 
satisfactory concerning the 90% predicted interval but less satisfactory for the median. The 
basic model was found to be a one compartment model with a first order absorption with a lag 
time, and a first order elimination. It was parameterized with the apparent volume of 
distribution (V/F), the apparent clearance (CL/F), the absorption rate constant (ka) and a lag 
time (Tlag). A correlation between CL/F and V/F and between ka and Tlag was estimated. A 
proportional error model was found to best describe the residual error model. The estimated 
population parameters are given in Table I. 
From that basic model, significant effects of the covariates on the individual estimates 
of the random effects were found for age, sex, race, weight, creatinine clearance, total plasma 
protein and alcohol habit. The final model with the lowest AIC, after performing backward 
elimination of the covariates included only a weight effect on V/F. The estimates of the 
population parameters of the final model are given in Table I. Goodness-of-fit plots are not 
shown here but were satisfactory. 
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EVALUATION BY SIMULATION: MODEL WITHOUT COVARIATE 
Simulation design 
We used the design of the second phase III study (number of subjects = 351 and number of 
observations = 973), the basic model and the parameters of Table I to simulate validation 
datasets (V). The null hypothesis (H0) is that data in the validation dataset V can be described 
by the model. We simulated 500 datasets V under the null hypothesis H0 in order to evaluate 
the type I error of different tests applied to several metrics or approaches. Simulation data 
were treated as the observations concerning BQL values. 
 
Metrics evaluated under H0 
We applied five metrics to each of the simulated datasets under H0. 
The first metric is SPE, which are frequently used to evaluate nonlinear mixed effect models 
because they were computed in the main software used in population PKPD analyses, 
NONMEM(11), where they are reported under the name weighted residuals (WRES). SPE are 
defined as the difference between the observations and the predictions, standardized by the 
variance-covariance matrix of the observations. For each individual, the mean value and 
variance are computed using the first-order approximation around the mean of the model like 
in the first order linearization approach used in NONMEM. Under H0 and assuming the first-
order approximation holds, the prediction errors SPEij, for a j
th
 observation of a i
th
 subject, 
should have a normal distribution with mean 0 and variance 1. SPE were computed under the 
name WRES using NONMEM for the validation datasets. 
We evaluated the second metric, pd, for each simulated dataset. pd are computed as the 
percentile of each observation in the simulated predictive distribution under H0 . Figure 2 
shows graphically how pd are obtained. For each observation (Yij), we perform Monte Carlo 
simulations to obtain the posterior predictive distribution and we compute the percentile of an 
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observation in the whole marginal predictive distribution. When the distribution of the pd is 
represented as a histogram, we expect a uniform distribution under H0.  
The third metric, NPDE, are obtained in a similar way as the pd, but using decorrelated 
and centered simulated and observed data(6). The empirical mean and variance of the 
simulated data for each subject are used for the decorrelation . By construction NPDEij follow 
a N(0, 1) distribution under H0 without any approximation. 
 Finally, we considered NPC, which compares the observations with their prediction 
intervals obtained by simulation. Observed data are often compared against different 
simulated predicted intervals obtained by simulation (8). We considered here classical NPC 
and another case developed here called NPCdec by taking into account correlations within 
individuals. The NPCdec approach consists in decorrelating and centering simulations and 
observations just before performing NPC as it is performed for the NPDE computation(6). 
 
 Several tests can be used in combination to test that a metric follows the N(0, 1) 
distribution: we use a Wilcoxon signed-rank test to test whether the mean is significantly 
different from 0, a Fisher test to test whether the variance is significantly different from 1, a 
Shapiro-Wilks test (SW) to test the normality assumption. We also define a global test, which 
consists in rejecting H0 if at least one of the three tests (mean, variance, normality) is 
significant with a Bonferroni correction (p=0.05/3). These four tests were applied to SPE and 
NPDE but also to the pd after a normalization step. 
 In order to compare NPC with the first three metrics, we propose to test if the 
percentage of observations outside a prediction interval was significantly different from the 
expected one. We use a Student test and a binomial exact test. From the 1000 simulations, the 
5
th
, 10
th
, 25
th
, 75
th
, 90
th
 and 95
th
 simulated percentiles for each observation were calculated 
and we computed the percentage of observations outside the 90%, 80% and 50% prediction 
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intervals (PI). We tested if these percentage of obsevations outside the different PI were not 
different from the expected one (under H0).  
For all the tests applied to these metrics, the type I error computed by simulation corresponds 
to determine the percentage of reject of H0, when H0 is true.  
 
 The simulation of the 500 validation datasets and the simulations used for pd, NPDE 
and NPC were performed with NONMEM version V. We performed 1000 simulations to 
implement the evaluation of pd, NPDE and NPC for each of the 500 simulated validation 
datasets V. SPE were computed with NONMEM (WRES item). The final computation of 
NPDE (and pd) was performed using R version 2.3.1. The statistical software SAS version 9.1 
and R were used to perform statistical analyses.  
 
Results 
The type I errors evaluated for the different tests on the 500 replications for the three metrics 
(SPE, pd and NPDE) are reported in Table II, while the results for NPC and NPCdec are given 
in Table III. The performances of the different tests were very poor for SPE. The type I errors 
were close to 100% for the normality and variance tests for SPE. The Wilcoxon signed rank 
test was the only one which has a type I error close to 5% (4.2%). As a result, the global test 
presented a type I error close to 100% for the SPE. 
The type I errors of all tests were higher than 5% (around 20%) for the pd after 
normalization. By taking into account correlation within individuals, the type I error of the 
global test based on the NPDE was close to 5%, confirming the good statistical properties of 
this metric. There was however a little increase of the type I error for the variance test (8.6%) 
and a slight decrease (3.0%) for the signed rank test.  
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The figure 1 is an illustration of a NPC with a 90% PI. In Table III, for the classical 
NPC, the percentage of observations outside the 90%, 80% and 50% PI was significantly 
different from the theoretical PI, in around 13% of the datasets for all the different percentiles 
(for both Student and exact Binomial tests). When we took into account correlations within 
individuals by performing NPCdec, we found a slight increase of the type I error of the Student 
test, but a type error close to 5% for the exact Binomial test. Thus the high type I error of the 
classical VPC approach can be explained by the correlation between observations. 
 
Only NPDE and NPCdec presented good statistical properties with these simulations. As 
NPCdec are very close to NPDE by computation, we decide in the following to extend only the 
application of NPDE to evaluate different models with a covariate. 
 
EVALUATION BY SIMULATION: MODELS WITH COVARIATES 
Simulation design 
As previously we used the design and the real covariate values of the second phase III study 
(number of subjects= 351 and number of observations=973) to simulate different validation 
datasets in order to evaluate the type I error and the power of different tests applied to NPDE 
for model with covariates. The final model only had a weight effect on V/F, but we chose to 
simulate a continuous covariate (weight) effect on V/F, or a categorical covariate (sex) effect 
on CL/F in order to evaluate models with different type of covariate (continuous and discrete). 
We generated external validation datasets under alternative assumptions, with different 
models: (i) M0, the basic model without covariate; (ii) MWT with a weight effect of 50% on 
V/F (a weight effect was simulated on V/F using equation (1) with and COV = 0.6; this 
corresponds to a 50% change of V/F between weight at the first quartile and at the third 
quartile); (iii) MSEX with a sex effect of 50% on CL/F. ; (a sex effect on CL/F was simulated 
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using equation (2) with and COV = 1.5 to obtain the same mean (= 0.88) than in 
Table I, and an increase of 50% of CL/F in women). For the other parameters of the models, 
we took the estimates obtained with the final model given in Table I.  
Thus we simulated 1500 validation datasets for each of three different assumptions with 
M0, MWT and MSEX to obtain these validation datasets: (i) 500 V0, without covariate; (ii) 500 
VWT, with a weight effect on V/F; (iii) and 500 VSEX with a sex effect on CL/F.  
 
Evaluation of models with covariates using NPDE 
For each of the 1500 validation datasets, we computed NPDE as previously using 1000 
simulations with the different models M0, MWT and MSEX. If the validation dataset and the 
model with which we computed NPDE were the same (V0 and M0, VWT and MWT, VSEX and 
MSEX), the number of times the model was rejected even though it was true was defined as the 
type I error. If the validation dataset and the model did not correspond (model 
misspecification), we defined the power as the number of times we rejected the model being 
tested.  
We propose two approaches based on NPDE to evaluate a model with or without 
covariates with a validation dataset. The first approach consists in using a Spearman 
correlation test for continuous variables, to test the relationship between NPDE and weight, 
and a Wilcoxon test for categorical variables, to test the relationship between NPDE and sex. 
If the model and validation datasets agree, there should be no relationship between NPDE and 
covariates and the test should not be significant. Scatterplots of NPDE versus the continuous 
covariate and box-plots of the NPDE split by the categorical covariate can be performed to 
display the link between NPDE and covariates. 
The second approach consists in testing whether the NPDE follow a N(0, 1) distribution 
after splitting them by covariates. If the covariate is continuous, we discretize it in several 
classes according to the quantiles. We choose here to categorize the weight effect into 3 
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classes: below first quartile (< Q1), between first and third quartiles (Q1-Q3) and above third 
quartile (> Q3). Again, we expect that NPDE does not significantly differ from a N(0, 1) 
distribution in any of the categories, if the model and validation datasets agree. Graphs of the 
cumulative density function (cdf) of NPDE can be plotted with the theoretical cdf overlaid, in 
order to visualize any departure of the NPDE distribution from the N(0, 1) distribution in each 
category or after splitting by quantiles. To test the N(0, 1) distribution of the NPDE, we 
consider the global test with a Bonferroni correction to take into account the number of 
covariate classes, since we found a type I error close to 5% for this test in the first series of 
simulations. NPDE were computed on the different validation datasets in order to evaluate the 
power of the different tests under the alternative assumptions.  
 
 
Results 
In the phase III study used to simulate the different validation datasets, the median value 
and the interquartile ranges for the covariate weight were respectively 85 (76-93) kg for men 
and 74 (64-83) kg for women. There were 61% of men and 39% of women.  
When model and validation dataset are consistent (M0 and V0), we found a type I error 
close to 5% for both approaches (5.4% and 6.6% respectively). Results are summarised in 
table IV for Spearman and Wilcoxon tests and in table V for the global test split by covariate. 
We obtained the same results for MWT and VWT, and MSEX and VSEX, i.e. under H0.  
Concerning the 500 validation datasets without covariate (V0), when we computed 
NPDE with a model with a weight effect (MWT), we found a power around 50% for the 
Spearman test. Figure 3 displays the box-plots between the NPDE and the weight effect 
categorized into 3 classes for one of the 500 V0. When NPDE were performed with a model 
with a sex effect (MSEX), we found a power of 100% for the Wilcoxon test. Figure 4 displays 
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the box-plots of the NPDE with respect to sex. We found the same results with the global tests 
split by covariates.We found the same results with the global tests split by covariates. We 
found a departure from a N(0, 1) distribution for sex and weight, especially for weight <Q1. 
Figure 5 displays an example of the cdf of the NPDE with the theoretical cdf overlaid, split by 
sex. 
Concerning the 500 validation datasets with a weight effect (VWT), when we computed 
NPDE with a model without covariate (M0), we found a power around 60% with the 
Spearman test, and slightly higher (67%) with the global test after splitting. For the 500 
validation datasets simulated with a sex effect (VSEX), we found for both approaches a high 
power to reject that the data came from M0.  
  
DISCUSSION 
Evaluation through prediction errors on observations, for instance using SPE, or WRES 
with NONMEM, were the most frequently used metrics for internal and external evaluation of 
PK and/or PD models. However commonly used diagnostics (like WRES based diagnostics) 
may falsely indicate that a model is inadequate (12). 
In the present paper, we first compared through simulations the statistical properties of 
recent metrics based on observations (NPDE, NPCdec) to SPE, pd and NPC.  
The computation of the SPE computed in NONMEM relies on a linear approximation of 
the mixed-effect model around the mean as in the first order estimation method. It is however 
known that the linearisation around the mean is poor if the model is highly nonlinear or if the 
inter-patient variability is large, and then the distribution of SPEij under H0 is no longer 
normal, which can explain the high type I error for the global test. This has already been 
shown by Mentré and Escolano when they showed the better performance of pd over SPE (5). 
We nonetheless evaluated SPE also here, because this metric is one of the most used to assess 
the performance of a model through goodness of fit plots so that we wanted to compare 
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NPDE with SPE. It is obvious from the present study that SPE should not be used as a model 
evaluation tool. Hooker et al. proposed computing another metric that they called conditional 
WRES (CWRES) in which the FOCE approximation is used for the computation of the mean 
and the variance of the model instead of the FO approximation (13). We did not evaluate 
CWRES, although they are indeed a better approach than the usual WRES Thus, a formal 
comparison of the performances of CWRES and NPDE in the same setting would be 
interesting. 
To test H0 using NPDE, we proposed to perform a mean test, a variance test, a 
normality test or a global test combining all three. We found here, using simulations, that the 
global test presented a type I error close to 5%, confirming the good theoretical statistical 
properties of the NPDE and providing a single p-value for model evaluation. The NPDE 
metric does not require any assumption on the distribution of the observations, and, when 
computed with a large number of simulations, has a known theoretical distribution which can 
be tested. In a previous work, Mentré and Escolano showed that prediction discrepancies 
presented a type I error close to 5% when there were one observation per patient but a higher 
value if there were more than one observation per patient(5). We found the same conclusions 
here by finding a type I error for all the tests higher than 5% (around 20%) for the pd. These 
results for pd show the need to decorrelate the NPDE.  
The VPC have been applied in several PK and/or PD analyses. A few extensions and/or 
application of classical VPC have been proposed to falicitate evaluation (3, 14). As this 
method is subjective, the evaluation of model adequacy depends on the appreciation of the 
modeller. The related statistic of VPC, NPC is also applied in model evaluation (8). 
Therefore, we propose here to use a test, which consists in a comparison between the 
percentage of observations outside a simulated prediction intervals and the theoretical 
expected value. This test on classical NPC however shows a significantly higher type I error 
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(13%) than the nominal level expected, due to the correlations introduced by multiple 
observations within subjects. Consequently we defined NPCdec, to take into account these 
correlations. We then obtained a type I error close to 5% using the exact binomial test for 
NPCdec. We observed that the type I error was slightly higher using the Student test despite 
the large number of observations, which should have made the normal approximation valid. 
The disadvantage of using NPCdec is that we need to choose a prediction interval to perform 
the test, or combine results from several prediction intervals, whereas with NPDE we obtain a 
single p-value taking into account the full distribution of the NPDE. An extension of VPC 
called the Quantified Visual predictive check (QVPC) presents the distribution of the 
observations as a percentage, thus regardless the density of the data, above and below the 
predicted median at each time point. However this technic is only visual and no test were 
performed or proposed (14). 
In the second part of this paper, we examined the application of NPDE to the evaluation 
of covariate models. During the building of the covariate model in a population analysis, plots 
are often generated to check potential covariate relationships (for example, plots of the 
posterior Bayes estimates of the parameters versus potential covariables, or the posterior 
Bayes estimate of the random effects versus potential covariates). The EMEA, in the 
guideline on reporting the results of population pharmacokinetic analyses, indicate that a 
conclusion of no covariate effect based solely upon inspection of graphical screening plots is 
usually not acceptable. 
Several methods are available to evaluate a model with covariate during the building 
process and during the final internal evaluation process. In this paper, we propose here, within 
the framework of external evaluation, to use NPDE. We suggest two approaches with tests 
based on NPDE to evaluate a model with or without covariates with a validation dataset. The 
first approach consists in using a Spearman correlation test for continuous variable, and a 
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Wilcoxon test for categorical variable to test the relationship between NPDE and covariates. 
The second approach consists in testing whether the NPDE follow a N(0, 1) distribution with 
a global test after splitting them by covariates. Regarding all the tests applied to the different 
metrics, the null hypothesis is that the model is correct, so we can only invalidate a model 
when we reject H0, never accept it. 
 
For covariate models, when model and validation dataset were consistent, type I error of 
the tests were close to 5% for both type of covariates used in the simuation (discret, 
continuous). When validation datasets and models were not consistent, the tests presented a 
high power to detect the correlation between NPDE and sex but only a power around 60% for 
NPDE and weight. This difference may reflect the simulation conditions we chose, i.e. the 
size of the weight effect relative to the of sex effect and the variability on the parameters. 
Graphs of parameters versus covariates showed only a small trend for both effects, but the 
power to detect relationships was high, partly because of the large number of observations in 
the validation dataset (n=351). 
A current limitation of npde concerns BQL concentrations, which the present version of 
npde does not handle properly. Recently, estimation methods that handle censored data by 
taking into account their contribution to the log-likelihood were implemented in Nonmem and 
Monolix (15), making them readily available to the general user. In the next extension to 
npde, we therefore plan to propose and implement a method to handle BQL data for models 
using these estimation methods. In the meanwhile, we suggest to remove times for which too 
many observations are BQL before computing npde, since otherwise they might bias the 
results of the tests. 
The population model developped here with an oral antidiabetic agent, gliclazide was 
used for all the simulations. The FO method is known to behave poorly during model building 
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It was used here only to provide estimates for the model used for simulation. However, the 
final model fits should be performed using FOCE or FOCE_INTER as appropriate. 
The example chosen here was a pharmacokinetic one. Of course these different 
approaches and in particular NPDE could be apply for different PK and/or PD models. No 
modification of implementation and interpretation concerning NPDE are expected. An 
example of NPDE application with a PD model was presented in (16). 
 
In conclusion, we recommend to use NPDE over SPE for external model evaluation 
(and therefore for internal model evaluation), since they do not depend on an approximation 
of the model and have good statistical properties. Moreover, NPDE are not as subject to 
interpretation as NPC, which also suffer from not accounting for within subject correlation. 
The exact binomial test applied to NPCdec may be an alternative to compute a statistic, but 
leaves the modeller with the choice of the prediction interval(s). An add-on package for the 
open source statistical package R, designed to compute NPDE, is available at 
www.npde.biostat.fr and discussed in Comets et al. (17). In that paper, its is also discussed 
the importance of choosing the number of simulation for NPDE computation. NPDE are also 
automatically computed with MONOLIX v2.4, a new software for population PK and/or PD 
analyses, which implements the SAEM algorithm (18). 
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Table I. Estimated population pharmacokinetic parameters of gliclazide MR for the basic and 
the final models (estimate and relative standard error of estimation, RSE). 
 
 
 
Population parameters Basic model  Final model 
  Estimate    RSE (%)      Estimate   RSE (%) 
CL/F (L/h)    0.91      2.3       0.88    2.0 
V/F (L)  19.7    10.9     27.0    5.9 
θweight       -        -       0.21   22.2 
ka (h
-1
)    0.32    20.0       0.38    9.1 
Tlag (h)    1.3      7.3       1.2    5.9 
ω²CL/F     0.19      6.3       0.19     6.3 
ω²V/F     0.12     13.9       0.07   16.4 
ω²ka     0.31     22.1       0.31   19.1 
ω²Tlag     0.60     29.1       0.60   30.1 
Cov(V-CL)    0.10     12.1       0.09   12.3 
Cov(ka-Tlag)    0.29     23.7       0.31   22.5 
σ²    0.04     15.4        0.03   17.6 
  23 
 
Table II: Type I error under H0 (in %) of the global test, Wilcoxon test, the Fisher test and the 
Shapiro-Wilks test (SW), for the standardized prediction errors (SPE), the prediction 
discrepancies (pd) and the normalized prediction errors (NPDE), evaluated on 500 
simulated datasets. 
 
 
   METRICS   
TEST SPE pd* NPDE 
Wilcoxon 4.2% 19.9% 3.0% 
Fisher 100% 15.4% 8.6% 
SW 100% 16.1% 6.2% 
    
Global 100% 24.6% 5.8% 
* after normalization 
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Table III: Type I error under H0 (in %) of the Student test and the exact Binomal test applied 
to NPC and NPCdec approaches, evaluated on 500 simulated datasets. 
 
 NPC   NPCdec  
PI Student test Binomial test  Student test Binomial test 
90% 12.0 13.0  7.4 6.2 
80% 14.0 13.2  7.8 6.8 
50% 13.4 13.4  4.6 4.6 
 
 
Table IV: Percentage of significant Spearman test for weight and Wilcoxon test for SEX 
applied to NPDE, evaluated on 500 simulated datasets. 
 
Validation dataset Model 
Weight 
(Spearman) 
Sex 
(Wilcoxon) 
V0 M0              5.4%*          5.4%* 
V0 MWT            52.0%            - 
VWT M0            61.6%            - 
V0 MSEX              - 100% 
VSEX M0              - 100% 
    *Type I error under H0 
 
Table V: Percentage of significant global test applied to NPDE, evaluated on 500 simulated 
datasets. 
 
 
 
Validation dataset Model Weight Sex 
V0 M0 6.6%* 6.6%* 
V0 MWT 52.8% - 
VWT M0 67.0% - 
V0 MSEX - 99.2% 
VSEX M0 - 99.6% 
      *Type I error under H0 
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Figures Legends 
 
 
Figure 1  Gliclazide plasma concentration normalized for a dose of 30 mg versus time. On 
the top plot, the black dots represent the observations and the dashed lines the 5
th
 and 95
th
 
percentiles of 1000 simulations. On the bottom plot, the black lines represent the 10
th
, 50
th
 and 
90
th
 percentiles of 1000 simulations. The gray lines represent the 10
th
, 50
th
 and 90
th
 percentiles 
of the observations. 
 
Figure 2 Illustration of how to compute prediction discrepancies (pd), also used to compute 
NPDE. In the left top plot, dots represent observed plasma concentrations versus time and the 
dashed lines represent the 90% predicted interval, obtained as the 5
th
 and 95
th
 percentiles of 
simulations. In the left bottom plot; the predicted distribution of an observed concentration 
(Yij) is represented in order to define the pd. In the right bottom plot, the distribution of pd is 
represented. 
 
Figure 3 Box-plots of the Normalized Prediction Distribution Errors (NPDE) versus a 
continuous covariate (weight) categorized into 3 classes. V0 denotes a dataset simulated under 
H0 with the model M0 and VWT a dataset simulated assuming an effect of weight on V/F 
(model MWT). In the left hand plot, NPDE were computed for V0 with simulations under M0; 
in the middle plot, NPDE were computed for VWT with simulations under M0; in the right 
hand plot, NPDE were computed for V0 with simulations under MWT. 
 
Figure 4 Box-plots of the Normalized Prediction Distribution Errors (NPDE) versus a 
categorical covariate (sex) with M for male and F for female. V0 denotes a dataset simulated 
under H0 with the model M0 and VSEX a dataset simulated assuming an effect of SEX on CL/F 
(model MSEX). In the left hand plot, NPDE were computed for V0 with simulations under M0; 
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in the middle plot, NPDE were computed for VSEX with simulations under M0; in the right 
hand plot, NPDE were computed for V0 with simulations under MSEX. 
 
Figure 5 Cumulative density function (cdf) plots of the Normalized Prediction Distribution 
Errors (NPDE) split by sex. In the top plots NPDE were computed for V0 with simulations 
under M0; in the middle plots, NPDE were computed for VSEX with simulations under M0; in 
bottom plots, NPDE were computed for V0 with simulations under MSEX. 
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